GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE

GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE

A GIP and GLP-1 dual receptor agonist, a pharmaceutical composition, and the use. In particular, the present application relates to a compound represented by formula I, a pharmaceutical composition comprising the compound, and the use of the compound as a GIP and GLP-1 dual receptor agonist in the f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ZHEN, Wenteng, SONG, Yunsong, HUANG, Yangqing, YUAN, Jiandong, CAI, Yue, GU, Jianing
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ZHEN, Wenteng
SONG, Yunsong
HUANG, Yangqing
YUAN, Jiandong
CAI, Yue
GU, Jianing
description A GIP and GLP-1 dual receptor agonist, a pharmaceutical composition, and the use. In particular, the present application relates to a compound represented by formula I, a pharmaceutical composition comprising the compound, and the use of the compound as a GIP and GLP-1 dual receptor agonist in the field of medicine. The compound represented by formula I exhibits excellent GIPR and GLP-1R agonist activity and excellent pharmaceutical activity in reducing blood sugar and controlling body weight, is a therapeutic drug having a clinical application prospect, and can be used for preventing and treating diseases such as diabetes, diabetes complications, obesity, or obesity complications.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP4317179A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP4317179A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP4317179A13</originalsourceid><addsrcrecordid>eNrjZPBw9wxQcPRzUXD3CdA1VHAJdfRRCHJ1dg0I8Q9ScHT39_MMDtFRCPBwDPJ1dHYNDfF0Bipw9vcN8A_2DPH099MBaw4NduVhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuASbGhuaG5paOhsZEKAEAZrgr-Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE</title><source>esp@cenet</source><creator>ZHEN, Wenteng ; SONG, Yunsong ; HUANG, Yangqing ; YUAN, Jiandong ; CAI, Yue ; GU, Jianing</creator><creatorcontrib>ZHEN, Wenteng ; SONG, Yunsong ; HUANG, Yangqing ; YUAN, Jiandong ; CAI, Yue ; GU, Jianing</creatorcontrib><description>A GIP and GLP-1 dual receptor agonist, a pharmaceutical composition, and the use. In particular, the present application relates to a compound represented by formula I, a pharmaceutical composition comprising the compound, and the use of the compound as a GIP and GLP-1 dual receptor agonist in the field of medicine. The compound represented by formula I exhibits excellent GIPR and GLP-1R agonist activity and excellent pharmaceutical activity in reducing blood sugar and controlling body weight, is a therapeutic drug having a clinical application prospect, and can be used for preventing and treating diseases such as diabetes, diabetes complications, obesity, or obesity complications.</description><language>eng ; fre ; ger</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240207&amp;DB=EPODOC&amp;CC=EP&amp;NR=4317179A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240207&amp;DB=EPODOC&amp;CC=EP&amp;NR=4317179A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHEN, Wenteng</creatorcontrib><creatorcontrib>SONG, Yunsong</creatorcontrib><creatorcontrib>HUANG, Yangqing</creatorcontrib><creatorcontrib>YUAN, Jiandong</creatorcontrib><creatorcontrib>CAI, Yue</creatorcontrib><creatorcontrib>GU, Jianing</creatorcontrib><title>GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE</title><description>A GIP and GLP-1 dual receptor agonist, a pharmaceutical composition, and the use. In particular, the present application relates to a compound represented by formula I, a pharmaceutical composition comprising the compound, and the use of the compound as a GIP and GLP-1 dual receptor agonist in the field of medicine. The compound represented by formula I exhibits excellent GIPR and GLP-1R agonist activity and excellent pharmaceutical activity in reducing blood sugar and controlling body weight, is a therapeutic drug having a clinical application prospect, and can be used for preventing and treating diseases such as diabetes, diabetes complications, obesity, or obesity complications.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPBw9wxQcPRzUXD3CdA1VHAJdfRRCHJ1dg0I8Q9ScHT39_MMDtFRCPBwDPJ1dHYNDfF0Bipw9vcN8A_2DPH099MBaw4NduVhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuASbGhuaG5paOhsZEKAEAZrgr-Q</recordid><startdate>20240207</startdate><enddate>20240207</enddate><creator>ZHEN, Wenteng</creator><creator>SONG, Yunsong</creator><creator>HUANG, Yangqing</creator><creator>YUAN, Jiandong</creator><creator>CAI, Yue</creator><creator>GU, Jianing</creator><scope>EVB</scope></search><sort><creationdate>20240207</creationdate><title>GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE</title><author>ZHEN, Wenteng ; SONG, Yunsong ; HUANG, Yangqing ; YUAN, Jiandong ; CAI, Yue ; GU, Jianing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP4317179A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHEN, Wenteng</creatorcontrib><creatorcontrib>SONG, Yunsong</creatorcontrib><creatorcontrib>HUANG, Yangqing</creatorcontrib><creatorcontrib>YUAN, Jiandong</creatorcontrib><creatorcontrib>CAI, Yue</creatorcontrib><creatorcontrib>GU, Jianing</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHEN, Wenteng</au><au>SONG, Yunsong</au><au>HUANG, Yangqing</au><au>YUAN, Jiandong</au><au>CAI, Yue</au><au>GU, Jianing</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE</title><date>2024-02-07</date><risdate>2024</risdate><abstract>A GIP and GLP-1 dual receptor agonist, a pharmaceutical composition, and the use. In particular, the present application relates to a compound represented by formula I, a pharmaceutical composition comprising the compound, and the use of the compound as a GIP and GLP-1 dual receptor agonist in the field of medicine. The compound represented by formula I exhibits excellent GIPR and GLP-1R agonist activity and excellent pharmaceutical activity in reducing blood sugar and controlling body weight, is a therapeutic drug having a clinical application prospect, and can be used for preventing and treating diseases such as diabetes, diabetes complications, obesity, or obesity complications.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP4317179A1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T08%3A56%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHEN,%20Wenteng&rft.date=2024-02-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP4317179A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true